access 64. Family Health International (FHI), Centre for the AIDS Programme of Research in South Africa. CAPRISA 004 trial: summary sheet of facts. Research Triangle Park, NC USA, July 2010. (http://www.caprisa.org/joomla/, accessed 3 August 2010). 65. Family Health International (FHI), Centre for the AIDS Programme of Research in South Africa. Factsheet: results of the CAPRISA 004 trial on the effectiveness of tenofovir gel for HIV prevention. Research Triangle Park, NC USA, July 2010. 66. CAPRISA (Centre for the AIDS Programme of Research in South Africa) [web site]. Backgrounder CAPRISA 004 trial to assess the effectiveness and safety of 1% tenofovir gel in preventing HIV infection (http://www.caprisa.org/joomla/Micro/CAPRISA%20004%20 Backgrounder_20%20July%202010.pdf, accessed 3 August 2010). 67. Positive Health, Dignity and Prevention. Technical consultation report. Geneva, UNAIDS, 2009 (http://data.unaids.org/pub/ Report/2009/20091128_phdp_mr_lr_en.pdf, accessed 30 August 2010). 68. Delivering HIV test results and messages for re-testing and counselling in adults. Geneva, World Health Organization, 2010 (http://whqlibdoc. who.int/publications/2010/9789241599115_eng.pdf, accessed 22 July 2010). 69. Malawi and Tanzania research shows promise in preventing HIV and sexually-transmitted infections. Washington, DC, The World Bank, July 2010 (http://econ.worldbank.org/WBSITE/EXTERNAL/EXTDEC/0,contentMDK:22649337~pagePK:64165401~piPK:64165026~the SitePK:469372,00.html, accessed 30 August 2010). 70. Strathdee SA et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet, 2010, published online July 20 DOI:10.1016/ S0140-6736(10)60743-X.
PROGRESS REPORT 2010
49